Minims Cyclopentolaathydrochloride Bausch + Lomb Ireland Limited (Cyclopentolate Hydrochloride)

Cyclopentolate hydrochloride blocks muscarinic acetylcholine receptors in the iris sphincter and ciliary body. This antagonism relaxes the sphincter muscle, causing pupil dilation, and paralyzes the ciliary muscle, eliminating accommodation, which together facilitate eye examinations and accurate refractive measurements.

The specific dose and frequency of cyclopentolate are determined by the prescribing eye care professional based on the clinical indication, patient age, and ocular condition. The prescriber will select the appropriate number of drops and timing for each examination.

Safety data for cyclopentolate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician in consultation with the patient.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Cyclopentolate is an anticholinergic that produces both mydriasis and cycloplegia, whereas phenylephrine is an adrenergic agonist that primarily dilates the pupil without affecting accommodation. Cyclopentolate provides a longer duration of cycloplegia, making it preferable for refraction, while phenylephrine is often used when only brief dilation is needed.

Store the ophthalmic solution at ambient temperature, preferably below 25 °C, in its original container. Protect it from direct light, moisture, and extreme temperatures. Keep the bottle tightly closed when not in use and discard any solution that appears discolored or contaminated.

Minims Cyclopentolate is applied topically to the eye as prescribed. Typically, one or more drops are instilled into the conjunctival sac of the target eye(s) using a sterile technique. The patient should be instructed to avoid touching the dropper tip to the eye or surrounding tissues.

Serious risks include acute angle‑closure glaucoma in susceptible individuals, systemic anticholinergic toxicity (e.g., severe dry mouth, tachycardia, confusion), and allergic reactions such as eyelid swelling or rash. Any sudden eye pain, vision loss, or systemic symptoms should prompt immediate medical evaluation.

Cyclopentolate should not be used in patients with a known hypersensitivity to the drug or other anticholinergics, and it is contraindicated in individuals with narrow‑angle or acute angle‑closure glaucoma unless specifically directed by an ophthalmologist. Caution is also advised in infants, young children, and the elderly.